PhoreMost, a UK-based biopharmaceutical company dedicated to drugging undruggable disease targets, has announced that it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, a pharmaceutical company developing therapies for diseases with unsatisfactory treatments. Under the terms of the agreement, PhoreMost will receive an upfront payment and research funding together with downstream success-based milestones.

PhoreMost will deploy its next-generation phenotypic screening platform, SITESEEKER, towards disease-relevant pathways nominated by Boehringer Ingelheim. Novel targets identified will be further validated and characterized by Boehringer Ingelheim as part of its internal Discovery Research pipeline. Boehringer Ingelheims Research programme is active in the fields of immunology and respiratory diseases, cardiometabolic diseases, oncology research and immuno-oncology, as well as diseases of the central nervous system.

The SITESEEKER platform is based on PhoreMosts core proprietary protein interference, or PROTEINi, technology. Using SITESEEKER, PhoreMost probes the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease, using the vast 3-D shape diversity of natural protein fragment (sub-domain) libraries. This enables the systematic unmasking of cryptic druggable sites, directly linking them to useful therapeutic functions.

Read the original here:
Working Together To Drug the Undruggable - Technology Networks